Kerstin Westman
1 – 50 of 81
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis
(
- Contribution to journal › Article
- 2022
-
Mark
The Sound of Interconnectivity; The European Vasculitis Society 2022 Report
(
- Contribution to journal › Article
-
Mark
Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases : consensus statements from the ERA-IWG and EUVAS
(
- Contribution to journal › Scientific review
- 2021
-
Mark
Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis : A multinational study
(
- Contribution to journal › Article
- 2020
-
Mark
Effect of Treatment on Damage and Hospitalization in Elderly Patients with Microscopic Polyangiitis and Granulomatosis with Polyangiitis
(
- Contribution to journal › Article
-
Mark
Malignancies in patients with antineutrophil cytoplasmic antibody-associated vasculitis : A population-based cohort study
(
- Contribution to journal › Article
- 2019
-
Mark
Det första steget för ett svenskt njurbytesprogram
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Renal relapse in antineutrophil cytoplasmic autoantibody-associated vasculitis : unpredictable, but predictive of renal outcome
(
- Contribution to journal › Article
-
Mark
Living Anonymous Renal Donors Do Not Regret : Intermediate and Long-Term Follow-Up with a Focus on Motives and Psychosocial Outcomes
(
- Contribution to journal › Article
- 2017
-
Mark
Long-term patient survival in a Swedish population-based cohort of patients with ANCA-associated vasculitis
(
- Contribution to journal › Article
-
Mark
Severe infection in antineutrophil cytoplasmic antibody-associated vasculitis
(
- Contribution to journal › Article
-
Mark
Clinical associations with venous thromboembolism in anti-neutrophil cytoplasm antibody-associated vasculitides
(
- Contribution to journal › Article
-
Mark
Long term azathioprine maintenance therapy in ANCA-associated vasculitis : combined results of long-term follow-up data
(
- Contribution to journal › Article
-
Mark
Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse
(
- Contribution to journal › Article
-
Mark
Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts
(
- Contribution to journal › Article
-
Mark
The European Vasculitis Society 2016 Meeting Report
(
- Contribution to journal › Article
- 2016
-
Mark
EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
(
- Contribution to journal › Article
-
Mark
ANCA-associated glomerulonephritis : Risk factors for renal relapse
(
- Contribution to journal › Article
- 2015
-
Mark
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
(
- Contribution to journal › Article
-
Mark
Outcome and Treatment of Elderly Patients with ANCA-Associated Vasculitis.
(
- Contribution to journal › Article
-
Mark
Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials.
(
- Contribution to journal › Article
-
Mark
NT-rådets ställningstagande till eculizumab är oacceptabelt
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Slutreplik, Diana Karpman och medförfattare : - NT-rådet bör omedelbart återkalla sitt beslut om eculizumab
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials
(
- Contribution to journal › Article
-
Mark
The long-term outcomes of systemic vasculitis.
(
- Contribution to journal › Scientific review
-
Mark
Declining Estimated Glomerular Filtration Rate and Its Association with Mortality and Comorbidity Over 10 Years in Elderly Women.
(
- Contribution to journal › Article
-
Mark
Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts.
(
- Contribution to journal › Article
- 2014
-
Mark
Comparison of phenotype and outcome in microscopic polyangiitis between europe and Japan.
(
- Contribution to journal › Article
-
Mark
Long-Term Follow-Up of Cyclophosphamide Compared with Azathioprine for Initial Maintenance Therapy in ANCA-Associated Vasculitis.
(
- Contribution to journal › Article
- 2013
-
Mark
Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear
(
- Contribution to journal › Article
-
Mark
Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis
(
- Contribution to journal › Article
-
Mark
Methotrexate remains a valuable option for remission induction of nonsevere antineutrophil cytoplasmic antibody-associated vasculitis: comment on the article by Faurschou et al Reply
(
- Contribution to journal › Letter
- 2012
-
Mark
How can we predict the risk of relapse in antineutrophil cytoplasmic antibody-associated vasculitis? Comment on the article by Walsh et al Reply
(
- Contribution to journal › Letter
-
Mark
A Novel C3 Mutation Causing Increased Formation of the C3 Convertase in Familial Atypical Hemolytic Uremic Syndrome.
(
- Contribution to journal › Article
-
Mark
Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up
(
- Contribution to journal › Article
-
Mark
Den transplanterade patienten på vårdcentralen och akuten.
(
- Contribution to journal › Article
-
Mark
Brief Report: Long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis
(
- Contribution to journal › Article
-
Mark
Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis
(
- Contribution to journal › Article
- 2011
-
Mark
Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index
(
- Contribution to journal › Article
-
Mark
Long-term patient survival in ANCA-associated vasculitis
(
- Contribution to journal › Article
-
Mark
The prognostic value of BVAS and VDI in ANCA-AAV
2011) 15th International Vasculitis/ANCA Workshop In Clinical and Experimental Immunology 164(Suppl. 1). p.121-121(
- Contribution to journal › Published meeting abstract
-
Mark
A Model to Predict Cardiovascular Events in Patients With Newly Diagnosed Wegener's Granulomatosis and Microscopic Polyangiitis
(
- Contribution to journal › Article
-
Mark
Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials.
(
- Contribution to journal › Article
-
Mark
A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis.
(
- Contribution to journal › Article
- 2010
-
Mark
A Model To Predict Cardiovascular Events In Patients With Newly Diagnosed Wegener'S Granulmoatosis And Microscopic Polyangiitis
2010) Annual Meeting of the British-Society-Rheumatology/Spring Meeting of British-Health-Professional-in-Rheumatology In Rheumatology 49. p.124-124(
- Contribution to journal › Published meeting abstract
-
Mark
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis.
(
- Contribution to journal › Article
- 2009
-
Mark
The association between relapses of ANCA-associated vasculitis and the composite endpoint of end-stage renal disease or death
(
- Contribution to journal › Published meeting abstract
-
Mark
Randomized trial of rituximab vs cyclophosphamide for ANCA-associated renal vasculitis: RITUXVAS
(
- Contribution to journal › Published meeting abstract
-
Mark
Long-term survival of ANCA-associated vasculitis
(
- Contribution to journal › Published meeting abstract
-
Mark
Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis A Randomized Trial
(
- Contribution to journal › Article